osteoarthritis
Conditions
Interventions
Group 2:Tranexamic acid ( intravenous injection) + Carbazochrome Sodium Sulfonate ( intravenous injection)
Group 3:Tranexamic acid ( intravenous injection) + Carbazochrome Sodium Sulfonate (Infiltration of the surrounding tissue of the capsule )
Group 4:Tranexamic acid ( intravenous injection)
Sponsors
Department of Orthopaedics, West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. patients with osteoarthritis and have to undergo TKA; 2. BMI: 20-35 kg/m2; 3. American Society of Anesthesiologists degree before operation: I~III grades; 4. Aged 18 years old and above;
Exclusion criteria
Exclusion criteria: 1. of tranexamic acid sodium and card collaterals, narcotic drug allergy; 2. the art side of the knee joint deformities (> 20 degree flexion deformity; Varus and valgus deformity > 20 degree) and joint rigidity; 3. An alcoholic or pregnant person; Use anticoagulants or contraceptives 5 days before surgery; 4. Repair part or total knee replacement, secondary osteoarthritis (rheumatoid arthritis, suppurative arthritis or post-traumatic arthritis); 5. The history of thromboembolic disease (DVT), pulmonary embolism (PE), coagulopathy, recent arterial thromboembolic events (such as myocardial infarction or stroke), hypercoagulability, hemophilia; 6. Severe cardiovascular and respiratory diseases; Kidney and liver failure, kidney transplantation history; 7. A person who refuses to participate in or refuse to accept blood products.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| total blood loss;haemoglobin;haematocrit;reduction in haemoglobin concentration;D-dimer; | — |
Secondary
| Measure | Time frame |
|---|---|
| transfusion rates;thromboelastogram;inflammatory cytokines;range of motion of the knee; | — |
Countries
China
Contacts
Public ContactPengde Kang
West China Hospital, Sichuan University
Outcome results
None listed